Seed · Biotech · Cambridge, United Kingdom · Founded 2022 · 11–50 employees
Syndex Bio is a biotechnology company developing molecular diagnostics based on its proprietary methyl-copying polymerase chain reaction platform. While traditional PCR strips away DNA methylation marks, this technology copies and amplifies both the native methylation patterns and the underlying genetic sequence simultaneously. The platform is designed to enable faster, highly sensitive analysis of methylated DNA for clinical applications such as early cancer detection from liquid biopsies. The company raised a fifteen point five million dollar seed round led by ARCH Venture Partners to scale its team and advance the platform.
No open roles listed right now.